Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves BREO ELLIPTA for the treatment of adults with asthma in the US

LONDON and SAN FRANCISCO, April 30, 2015 /PRNewswire/ — GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is not indicated for the […]

Read More »

Eisai and Glenmark Reach Settlement over Generic Version of BANZEL (rufinamide)

WOODCLIFF LAKE, N.J., April 30, 2015 /PRNewswire/ — Eisai Inc. and Eisai Co., Ltd. have entered into a settlement agreement with Glenmark Pharmaceuticals, Ltd., Glenmark Generics Ltd., and Glenmark Generics, Inc., USA (“Glenmark”), to resolve their patent litigation relating to Eisai’s BANZEL® (rufinamide) in the United States. As a result of the settlement, Glenmark will be […]

Read More »

Celgene sales highlight Revlimid dependence ahead of patent ruling

(Reuters) – Celgene Corp’s dependence on its big-selling multiple myeloma drug Revlimid raised investor concerns on Thursday as sales of its other medicines fell short of expectations. Celgene shares fell 5 percent after the company reported quarterly results in which Revlimid shored up profits. Industry analysts see room for Revlimid to grow much further, with […]

Read More »

Nexium, Advair led Medicare drug spending in 2013 – officials

(Reuters) – Four brand-name medications accounted for almost one-tenth of the $103 billion in prescriptions filled by older or disabled Americans under Medicare’s drug program in 2013, U.S. officials reported on Thursday. The Centers for Medicare and Medicaid Services (CMS) said AstraZeneca Plc’s Nexium “purple pill” for acid reflux topped the list with prescriptions totaling […]

Read More »

IMS Health Finds Wide Disparity Between Essential Medicines List of WHO and Several Pharmerging Countries

DANBURY, Conn.–(BUSINESS WIRE)–The high level of disparity between the World Health Organization’s Model Essential Medicines List (EML) and the EMLs of nine pharmerging countries was highlighted in remarks by Murray Aitken, executive director of the IMS Institute for Healthcare Informatics, at the WHO’s Expert Committee session on April 20. At the Geneva meeting, Aitken presented […]

Read More »

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) for the treatment of previously untreated patients with unresectable or metastatic melanoma. The FDA also granted Priority Review for this application. The projected FDA […]

Read More »

Breckenridge Announces Approval for Repaglinide Tablets, USP

BOCA RATON, Fla., April 29, 2015 /PRNewswire/ — Breckenridge Pharmaceutical, Inc. announces the final approval by the U.S. Food and Drug Administration of the Abbreviated New Drug Application for Repaglinide Tablets USP, which is being manufactured and supplied by Standard Chem. & Pharm. Co., Ltd. Taiwan, and will be available in 0.5mg, 1mg, and 2mg strengths. […]

Read More »

Express Scripts says controlling cancer-drug costs a tough new focus

(Reuters) – Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new “focus area” will be subduing costs of a growing wave of pricey biotech cancer drugs. “This is going to be a much slower and much bigger effort over time than […]

Read More »

DNA Sequencing Market Will Exceed $20 Billion, Says Illumina CEO Jay Flatley

Illumina, one of the most important companies in biomedicine, is still barely known to the public. But scientists, diagnostics makers, physicians, and Wall Street look at the company with a mix of fear and awe. Just as Intel became the company that sparked so much of the computer revolution, Illumina has risen to prominence as […]

Read More »

BONESUPPORT Announces CE-Mark of CERAMENT|V, the First Injectable Vancomycin Eluting Bone Substitute in the Management of Osteomyelitis

LUND, Sweden, April 29, 2015 /PRNewswire/ — BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received CE-mark for CERAMENT™|V, the first injectable vancomycin eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.  CERAMENT™|V is […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom